Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/85cf1839-5d87-4b1b-8118-600d01682cf0/

VRTX

Vertex Pharmaceuticals Inc
Chart
$446.83
Latest Week 2026-06-05
HealthcareBiotechnologyLARGE
Snapshot 2026-06-07 · 0.0w · Fresh
0.11
OS Score
7.0%
Value
84.0%
Quality
21.0%
Momentum
4/9
F-Score
0.242
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
1 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
ROE 22%
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
7.0%ile
P/E
26.4×
P/S
9.3×
P/B
5.9×
E/P
0.0379
FCF Yield
0.044
EBITDA/EV
0.048
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
95.00000000
/100 — 1=cheapest
VC2 (Trending Value)
97.00000000
/100
VC3 (Buyback)
97.00000000
/100
VC2 score of 97.00000000/100 — expensive across all six composite measures.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
84.0%ile
ROE
0.224
ROA
0.164
Net Margin
0.354
Op Margin
0.410
GPA
0.399
D/E
0.37
Current
3.02
F-Score
4/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.104
Stability
3.891
lower=better
Accruals
0.004
lower=better
5yr Consist
No
ROE of 22% is exceptional. Conservative balance sheet with D/E of 0.37.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
21.0%ile
6M Return
-1.9%
12M Return
-0.8%
12-1 Mom
-4.6%
Risk-Adj
-0.15
Vol 252d
30.6%
Vol 60d
50.3%
↑ Expanding
Max DD 12M
-22.0%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
Near-term vol (50%) is expanding vs long-term (31%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.11
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
2.2%
Sector Quality %ile
87.8%
P/E z-score
0.01
P/B z-score
0.08
Sector Avg OS
63.3%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
IRWD Ironwood Pharmaceuticals Inc 99.0% 93.0% 86.0% 98.0%
FBIO Fortress Biotech Inc 98.0% 97.0% 93.0% 74.0%
RIGL Rigel Pharmaceuticals Inc 98.0% 94.0% 92.0% 76.0%
CGEN Compugen 97.0% 90.0% 95.0% 76.0%
PBYI Puma Biotechnology Inc 97.0% 80.0% 97.0% 92.0%
FBIOP Fortress Biotech Inc Pref Series A 97.0% 81.0% 95.0% 90.0%
WW WW International, Inc. Common Stock 97.0% 88.0% 80.0% 99.0%
MD Mednax Inc 96.0% 87.0% 80.0% 87.0%
Factor Interactions
Quality at a Premium
High quality (84th) but expensive (7th value). Upside may be limited without earnings growth.
Volatility Expanding
60-day vol (50%) significantly exceeds 252-day (31%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
D
32.1% avg (7 factors)
Quality
A
84.4% avg (8 factors)
Momentum
F
29.0% avg (4 factors)
Risk
B
65.7% avg (1 factors)
High quality business commanding a premium price. The market recognises the quality — returns from here depend on continued fundamental execution. Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.110—1—
Value %ile0.070—1—
Quality %ile0.840—1—
Momentum %ile0.210—1—
F-Score4.000—1—
Confidence0.970—1—
Volatility0.306—0—
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
26.40
Earnings Yield (E/P)
0.0379
Price / Sales
9.34
Price / Book
5.91
Price / Cash Flow
27.01
FCF Yield
4.4%
EBITDA / EV
4.8%
Sales Yield (1/P·S)
0.1123
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
22.4%
Return on Assets
16.4%
Net Margin
35.4%
Operating Margin
41.0%
Gross Profit / Assets
Novy-Marx GPA
39.9%
Debt / Equity
0.37
Current Ratio
3.02
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.004
MomentumPrice trend strength over different horizons
6M Return
-1.9%
12M Return
-0.8%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
-4.6%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
-0.15
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
10.4%
Earnings Stability (CV)
Lower = more stable
3.891
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
4
Dividend Yield
0.0%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
95
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
97
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
97
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity